Trial · NCT01772004
Participant flow138
How many started, completed or left each group, period by period.
1 to 20 of 138
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Dose Escalation Phase | STARTED | Dose Escalation Cohort: Avelumab 1.0 mg/kg | 4 | |
| Dose Escalation Phase | STARTED | Dose Escalation Cohort: Avelumab 3.0 mg/kg | 13 | |
| Dose Escalation Phase | STARTED | Dose Escalation Cohort: Avelumab 10.0 mg/kg | 15 | |
| Dose Escalation Phase | STARTED | Dose Escalation Cohort: Avelumab 20.0 mg/kg | 21 | |
| Dose Escalation Phase | STARTED | Dose Escalation Cohort: Avelumab 10.0 mg/kg Weekly | 8 | |
| Dose Escalation Phase | STARTED | Primary Expansion Cohort: NSCLC, Post-platinum Doublet | 0 | |
| Dose Escalation Phase | STARTED | Primary Expansion Cohort: NSCLC, First Line | 0 | |
| Dose Escalation Phase | STARTED | Primary Expansion Cohort: Metastatic Breast Cancer | 0 | |
| Dose Escalation Phase | STARTED | Primary Expansion Cohort: GC/GEJC Progressed | 0 | |
| Dose Escalation Phase | STARTED | Primary Expansion Cohort: GC/GEJC Non Progressed | 0 | |
| Dose Escalation Phase | STARTED | Secondary Expansion Cohort: Colorectal Cancer | 0 | |
| Dose Escalation Phase | STARTED | Secondary Expansion Cohort: Castrate-resistant Prostate Cancer | 0 | |
| Dose Escalation Phase | STARTED | Secondary Expansion Cohort: Adrenocortical Carcinoma | 0 | |
| Dose Escalation Phase | STARTED | Secondary Expansion Cohort: Melanoma | 0 | |
| Dose Escalation Phase | STARTED | Secondary Expansion Cohort: Mesothelioma | 0 | |
| Dose Escalation Phase | STARTED | Secondary Expansion Cohort: Urothelial Carcinoma | 0 | |
| Dose Escalation Phase | STARTED | Secondary Expansion Cohort: Ovarian Cancer | 0 | |
| Dose Escalation Phase | STARTED | Secondary Expansion Cohort: Renal Cell Carcinoma (First Line) | 0 | |
| Dose Escalation Phase | STARTED | Secondary Expansion Cohort: Renal Cell Carcinoma (Second Line) | 0 | |
| Dose Escalation Phase | STARTED | Efficacy Expansion Cohort: Ovarian Cancer | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01772004/flow